NVAX · Novavax Inc
$7.88
-0.33 (-4.02%)
At close · Jul 20
Market Cap
$1.30B
Shares
164.44M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.12B
+64.7%
FY2025
Net Income
$440.3M
+334.8%
FY2025
Gross Margin
93.5%
+23.2pp
FY2025
Operating Margin
40.3%
+76.8pp
FY2025
Diluted EPS
$2.58
+309.8%
FY2025
Operating Cash Flow
-$244.64M
-180.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $230M – $270M* | $596.34M | $1.12B | $682.16M | $983.71M | $1.98B | $1.15B | $475.6M | $18.66M | $34.29M | $31.18M | $15.35M | $36.25M | $30.66M | $20.92M | $22.08M | $14.69M | $343K | — | |
| — | $89.62M | $73.04M | $202.74M | $343.77M | $902.64M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| — | $506.72M | $1.05B | $479.42M | $639.94M | $1.08B | $1.15B | $475.6M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | 93.5% | 70.28% | 65.05% | 54.46% | 100% | 100% | — | — | — | — | — | — | — | — | — | — | — | |
| — | $348.86M | $342.32M | $391.17M | $737.5M | $1.24B | $2.53B | $747.03M | $113.84M | $173.8M | $168.44M | $237.94M | $162.64M | $94.42M | $58.53M | $26.91M | $18.36M | $28.03M | $25.78M | |
| — | — | — | — | $468.95M | $488.69M | $298.36M | $145.29M | $34.42M | $34.41M | $34.45M | $46.53M | $30.84M | $19.93M | $14.82M | $10.14M | $10.9M | $10.81M | $11.93M | |
| — | — | $157.48M | $337.19M | $468.95M | $488.69M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | $400K | $600K | $700K | $700K | $2.2M | $800K | $900K | $1.1M | $500K | — | — | — | — | |
| — | — | $28M | $48M | $41M | $29M | $13M | $4.3M | $5.1M | $7.4M | $7.6M | $7.7M | $5.1M | $4.4M | $2.6M | $1.7M | $1.6M | $1.4M | $1.19M | |
| — | — | — | — | $14.58M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $674.49M | $670.68M | $931.09M | $1.55B | $2.63B | $2.83B | $892.32M | $139.24M | $208.21M | $202.89M | $284.47M | $193.49M | $114.35M | $73.35M | $51.74M | $36.27M | $38.84M | $37.71M | |
| — | -$78.15M | $452.8M | -$248.93M | -$566.51M | -$644.74M | -$1.69B | -$416.72M | -$120.58M | -$173.92M | -$171.71M | -$269.11M | -$157.24M | -$83.69M | -$52.43M | -$29.67M | -$21.58M | -$38.49M | -$37.38M | |
| — | — | 40.3% | -36.49% | -57.59% | -32.53% | -147.13% | -87.62% | -646.13% | -507.23% | -550.78% | -1752.84% | -433.75% | -272.97% | -250.7% | -134.38% | -146.92% | -11222.74% | — | |
| — | — | $480.8M | -$200.93M | -$525.51M | -$615.74M | -$1.67B | -$412.42M | -$115.48M | -$166.52M | -$164.11M | -$261.41M | -$152.14M | -$79.29M | -$49.83M | -$27.97M | -$19.98M | -$37.09M | -$36.19M | |
| — | $21.73M | $22.55M | $20.08M | $14.42M | $19.88M | $21.13M | $15.15M | $13.61M | $13.61M | $14.07M | $12.97M | $241K | $157K | $160K | $32K | $9000 | $9000 | $786K | |
| — | $28.6M | $29.5M | $37.2M | $20.1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $42.4M | $40.63M | $40.44M | $37.9M | $10.97M | -$6.83M | $13.61M | -$13K | $108K | $67K | -$31K | -$120K | $0 | $182K | $45K | $26K | $485K | — | |
| — | -$86.19M | $442.17M | -$176.62M | -$543.03M | -$653.65M | -$1.71B | -$418.26M | -$132.69M | — | — | — | -$156.94M | -$82.95M | -$51.96M | -$28.51M | -$18.95M | -$36.16M | -$40.35M | |
| — | $1.65M | $1.87M | $10.88M | $2.03M | $4.29M | $29.22M | $0 | $0 | — | — | — | $0 | $0 | $25K | $0 | $412K | $450K | — | |
| — | -$87.84M | $440.3M | -$187.5M | -$545.06M | -$657.94M | -$1.74B | -$418.26M | -$132.69M | -$184.75M | -$183.77M | -$279.97M | -$156.94M | -$82.95M | -$51.98M | -$28.51M | -$19.36M | -$35.71M | -$40.35M | |
| — | — | 39.19% | -27.49% | -55.41% | -33.2% | -152.12% | -87.94% | -711.04% | -538.81% | -589.46% | -1823.53% | -432.93% | -270.55% | -248.54% | -129.13% | -131.84% | -10410.5% | — | |
| — | -$87.84M | $440.3M | -$187.5M | -$545.06M | — | — | — | — | — | — | — | — | — | — | -$28.51M | -$19.36M | -$35.71M | — | |
| — | -$94.52M | $464.87M | -$212.78M | -$535.96M | -$662.96M | -$1.75B | -$398.73M | -$134.01M | -$187.32M | -$180.57M | -$282.66M | -$159.46M | -$90.39M | -$51.57M | -$28.91M | -$19.3M | -$35.76M | — | |
| USD/shares | — | — | $2.72 | -$1.23 | -$5.41 | -$8.42 | -$23.44 | -$7.27 | -$5.51 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | $2.58 | -$1.23 | -$5.41 | -$8.42 | -$23.44 | -$7.27 | -$5.51 | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 161.99M | 152.19M | 100.77M | 78.18M | 74.4M | 57.55M | 24.1M | 18.49M | 14.63M | 270.8M | 262.25K | 225.85K | 169.66M | 131.73K | 113.61K | 104.77K | — |
| shares | — | — | 173.1M | 152.19M | 100.77M | 78.18M | 74.4M | 57.55M | 24.1M | 18.49M | 14.63M | 270.8M | 262.25K | 225.85K | 169.66M | 131.73K | 113.61K | 104.77K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.20×
P/E (TTM)
—
Biotechnology median 7.03×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $1,123,479,000 | $682,162,000 | $983,705,000 | $1,981,872,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Rest of North America | $575,670,000 | $4,462,000 | $13,388,000 | $194,480,000 |
| United States | $405,611,000 | $522,535,000 | $443,894,000 | $382,921,000 |
| Rest of the World | $126,458,000 | $59,022,000 | $254,459,000 | $577,642,000 |
| Europe | $15,740,000 | $96,143,000 | $271,964,000 | $826,829,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $685,041,000 | $213,202,000 | $547,889,000 | $1,554,961,000 | $0 | $0 | — | — |
| Nuvaxovid Sales | $625,182,000 | $190,212,000 | $531,389,000 | — | — | — | — | — |
| Licensing Royalties and Other | $438,438,000 | $468,960,000 | $8,493,000 | $43,990,000 | — | — | — | — |
| Supply Sales | $59,859,000 | $22,990,000 | $16,500,000 | — | — | — | — | — |
| Grant | $0 | $0 | $427,323,000 | $382,921,000 | $948,709,000 | $453,210,000 | $15,937,000 | $34,288,000 |
| License Fees and Sales-Based Royalties | — | $398,200,000 | — | — | — | — | — | — |
| Milestone Payments | — | — | — | $20,000,000 | $20,000,000 | — | — | — |
| Royalties and Other | — | — | $24,993,000 | $43,990,000 | $197,581,000 | $22,388,000 | $2,725,000 | — |
| Sales-Based Royalties | — | — | $8,500,000 | $9,000,000 | $178,600,000 | — | — | — |
| Government Contract | — | — | — | — | — | — | — | $0 |
Key facts
CIK
1000694
CUSIP
670002401
13F (30d)
21 filings
21 filers
Visit website
Investor relations